| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KRT13 |
| Uniprot No | P13646 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-458aa |
| 氨基酸序列 | MSLRLQSSSASYGGGFGGGSCQLGGGRGVSTCSTRFVSGGSAGGYGGGVSCGFGGGAGSGFGGGYGGGLGGGYGGGLGGGFGGGFAGGFVDFGACDGGLLTGNEKITMQNLNDRLASYLEKVRALEEANADLEVKIRDWHLKQSPASPERDYSPYYKTIEELRDKILTATIENNRVILEIDNARLAADDFRLKYENELALRQSVEADINGLRRVLDELTLSKTDLEMQIESLNEELAYMKKNHEEEMKEFSNQVVGQVNVEMDATPGIDLTRVLAEMREQYEAMAERNRRDAEEWFHTKSAELNKEVSTNTAMIQTSKTEITELRRTLQGLEIELQSQLSMKAGLENTVAETECRYALQLQQIQGLISSIEAQLSELRSEMECQNQEYKMLLDIKTRLEQEIATYRSLLEGQDAKMIGFPSSAGSVSPRSTSVTTTSSASVTTTSNASGRRTSDVRRP |
| 预测分子量 | 57.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与KRT13重组蛋白相关的参考文献示例及摘要概括：
---
1. **文献名称**: *"Recombinant expression and characterization of human keratin 13 in Escherichia coli"*
**作者**: Smith J, et al.
**摘要**: 本研究成功构建了人源KRT13基因的重组表达载体，并利用大肠杆菌表达系统高效表达可溶性KRT13蛋白。通过镍柱亲和层析纯化获得高纯度蛋白，并验证其与天然KRT13的免疫反应性，为后续抗体开发提供基础。
---
2. **文献名称**: *"Functional analysis of recombinant KRT13 in epithelial cell differentiation"*
**作者**: Lee S, Kim D, Park H.
**摘要**: 通过哺乳动物细胞表达系统(如HEK293)重组表达KRT13蛋白，研究其在口腔上皮细胞分化中的作用。结果显示重组KRT13参与细胞骨架稳定性调控，并影响细胞迁移能力，提示其在黏膜修复中的潜在应用。
---
3. **文献名称**: *"Production of recombinant KRT13 for serological diagnosis of oral lichen planus"*
**作者**: Gupta R, et al.
**摘要**: 开发基于重组KRT13蛋白的ELISA检测方法，用于口腔扁平苔藓患者的自身抗体筛查。研究证实重组蛋白具有高灵敏度和特异性，可作为临床诊断的新型生物标志物。
---
4. **文献名称**: *"Structural insights into keratin 13 mutations associated with white sponge nevus"*
**作者**: Chen X, et al.
**摘要**: 通过重组表达携带致病突变的KRT13蛋白，结合X射线晶体学分析其结构变化，揭示突变导致蛋白二聚化异常及细胞角蛋白网络破坏的分子机制，为遗传性黏膜疾病的治疗提供理论依据。
---
注：以上文献为示例性内容，实际文献需通过PubMed/Google Scholar等平台以关键词“recombinant KRT13 protein”或“keratin 13 expression”检索获取。
Keratin 13 (KRT13) is a member of the type I keratin family, a group of intermediate filament proteins critical for maintaining the structural integrity and mechanical stability of epithelial cells. It is primarily expressed in non-cornified stratified epithelia, including mucosal tissues of the oral cavity, esophagus, and vagina, where it pairs with keratin 4 (KRT4) to form heterodimeric filaments. KRT13 plays a key role in cell differentiation, tissue resilience, and protection against mechanical stress. Dysregulation of KRT13 has been linked to pathological conditions such as oral lichen planus, leukoplakia, and esophageal squamous cell carcinoma, where its downregulation is often associated with disease progression.
Recombinant KRT13 protein is produced using biotechnological platforms (e.g., bacterial, yeast, or mammalian expression systems) to enable controlled in vitro studies. The recombinant form retains functional domains essential for polymerization, allowing researchers to investigate its interactions with binding partners, regulatory mechanisms, and role in epithelial homeostasis. Its applications span basic research, diagnostic assay development, and therapeutic exploration. For example, it is used to study epithelial-mesenchymal transition (EMT) in cancer, develop biomarkers for early cancer detection, or engineer biomimetic scaffolds for regenerative medicine. Additionally, recombinant KRT13 serves as an antigen for antibody production in immunohistochemistry or ELISA, aiding in tissue-specific diagnostics. Ongoing studies focus on its potential as a therapeutic target to modulate epithelial integrity in genetic or inflammatory disorders.
×
